Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: results of a multicenter study after 12 months

Guerra Veloz, María Fernanda; Vázquez Morón, Juan María; Belvis Jiménez, María; Pallarés Manrique, Héctor; Valdés Delgado, Teresa; Castro Laria, Luisa; Maldonado Pérez, Belén; Benítez Roldán, Antonio; Perea Amarillo, Raúl; Merino, Vicente; Caunedo Álvarez, Ángel; Vilches-Arenas, Ángel; Argüelles Arias, Federico.
Rev. esp. enferm. dig ; 110(9): 564-570, sept. 2018. tab, graf
Artículo en Inglés | IBECS (España) | ID: ibc-177777

Documentos relacionados

  1. Clinical outcomes and cost savings of a nonmedical switch to a biosimilar in children/young adults with inflammatory bowel disease.
  2. Outcomes of Patients With Inflammatory Bowel Diseases Switched From Maintenance Therapy With a Biosimilar to Remicade.
  3. Similar Growth Outcomes in Children with Inflammatory Bowel Disease Initiated on Infliximab Originator or Biosimilar.
  4. Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study.
  5. Biosimilars for Pediatric Patients With Inflammatory Bowel Disease: Pediatric Gastroenterology Clinical Practice Survey.
  6. Comparison of the Pharmacokinetics of CT-P13 Between Crohn's Disease and Ulcerative Colitis.
  7. Rapid Infliximab Biosimilar Infusion in Children With Inflammatory Bowel Disease.
  8. Comparison of original and biosimilar infliximab (CTP-13) in biologic-naïve patients with Crohn's disease and ulcerative colitis: a retrospective, multicenter real-life study in Spain.
  9. PERFUSE: Non-Interventional Cohort Study of Patients Receiving Infliximab Biosimilar SB2: Results in Pediatric Patients.
  10. [Therapeutic antibodies in rheumatology].